Catalent (NYSE: CTLT) stock holders have a right to kick themselves right at present. For the company was subject to - at least a rumoured - bid for the entire company just recently. There was also an actual mini-tender for some of the stock. Both of which were at significantly higher prices than today's rather dismal performance. At which point there's that old saw about a bird in the hand, or even cash now being a good idea.
Catalent is a contract drug manufacturer. Management would probably argue at that description but that's close enough to what it really does. It is, supposedly, more efficient at the process of actually producing the drugs, pills and injections which make up so much of modern medicine. This means that a smaller company with a new drug doesn;t need to go through the entire process of building a production line. Gain FDA approval for whatever that new thing is and be able to get to market faster and with lower capital costs. Great, it's a useful function in the system.

Catalent stock price from NASDAQ
This doesn't work so well when Catalent turns out not to be so much more productive: “Catalent (NYSE: CTLT) is delaying the filing of its FQ3 results and noted that it expects to significantly reduce its fiscal 2023 net revenue and adjusted EBITDA outlook by more than $400M each.” The background problem is productivity at several plants. That clearly has impacts upon both costs and revenues. But there will also be accounting issues on the balance sheet - if the plants are less productive then are they also of lower capital value?
That's what has prompted this 25% drop in CTLT yesterday.
But there are also those other two issues. Danaher was said to be pursuing Catalent for a takeover at significantly above the then price of $70 per share (about). Then came the report of the productivity problem, which dropped the stock into the $40s. At which point there was a mini-tender offer in the low $40s. Firmly rejected by management and they recommended against stockholders taking it. Then came that latest report on the accounting problems - dealing with the productivity problems - which dropped the stock again this another 25% into the mid-$30s.
TRC Capital might well want to think about withdrawing that mini-tender offer in fact. Otherwise there's a great gaping gap where we can buy at market and tender into that offer.



